Frontiers in oncology · 2026
Cell secretome as a potential anticancer therapeutic agent: composition, mechanisms, preclinical evidence, and translational challenges.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Alrushaid Noor, AlQurashi Naif A, Alobaidi Bayan Saeed, Khan Firdos Alam
Аннотация
OBJECTIVE: This study aimed to critically review the current evidence on the anticancer potential of the cell-derived secretome, with emphasis on mesenchymal stem/stromal cell (MSC) products, and to provide a realistic translational roadmap.
METHODS: This narrative review analyzes preclinical studies (in vitro) published from 2000 until September 30, 2025, identified through PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar. We focused on the secretome composition, its source-dependent variability, the reported antitumor mechanisms, and the factors responsible for the conflicting pro- versus anti-tumorigenic outcomes. This narrative review covers the literature from January 2000 up to December 1, 2025 (final search: PubMed/MEDLINE, Scopus, Web of Science, ClinicalTrials.gov; terms: "secretome" OR "exosome" AND "cancer" AND "clinical trial").
KEY FINDINGS: Numerous preclinical studies demonstrate that certain MSC-derived secretomes-particularly inflammatory-primed, serum-free preparations from perinatal tissues (Wharton's jelly or umbilical cord) and extracellular vesicle (EV)-depleted or genetically/drug-loaded variants-consistently reduce the cancer cell viability, migration, angiogenesis, and tumor growth (55%-85% inhibition in rodent models) across breast, prostate, lung, glioma, and melanoma models. Conversely, unprimed adult tissue MSC secretomes and intact exosome fractions frequently exert neutral or tumor-promoting effects. Engineered platforms (e.g., TRAIL- or azurin-expressing MSCs and paclitaxel-primed amniotic cells) achieve the largest potency gains (from 10- to 100-fold) and favorable safety profiles in vivo. To date, no clinical trial has reported on the anticancer efficacy of any cell-free secretome product in humans.
TRANSLATIONAL IMPLICATIONS: Clinical advancement requires immediate consensus on an optimal perinatal-sourced candidate, mandatory priming/EV depletion, validated quantitative potency assays, and Good Manufacturing Practice (GMP)-compliant manufacturing. With coordinated effort, first-in-human phase I trials could commence by 2028-2029, offering a novel, off-the-shelf paracrine therapy for solid tumors.
METHODS: This narrative review analyzes preclinical studies (in vitro) published from 2000 until September 30, 2025, identified through PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar. We focused on the secretome composition, its source-dependent variability, the reported antitumor mechanisms, and the factors responsible for the conflicting pro- versus anti-tumorigenic outcomes. This narrative review covers the literature from January 2000 up to December 1, 2025 (final search: PubMed/MEDLINE, Scopus, Web of Science, ClinicalTrials.gov; terms: "secretome" OR "exosome" AND "cancer" AND "clinical trial").
KEY FINDINGS: Numerous preclinical studies demonstrate that certain MSC-derived secretomes-particularly inflammatory-primed, serum-free preparations from perinatal tissues (Wharton's jelly or umbilical cord) and extracellular vesicle (EV)-depleted or genetically/drug-loaded variants-consistently reduce the cancer cell viability, migration, angiogenesis, and tumor growth (55%-85% inhibition in rodent models) across breast, prostate, lung, glioma, and melanoma models. Conversely, unprimed adult tissue MSC secretomes and intact exosome fractions frequently exert neutral or tumor-promoting effects. Engineered platforms (e.g., TRAIL- or azurin-expressing MSCs and paclitaxel-primed amniotic cells) achieve the largest potency gains (from 10- to 100-fold) and favorable safety profiles in vivo. To date, no clinical trial has reported on the anticancer efficacy of any cell-free secretome product in humans.
TRANSLATIONAL IMPLICATIONS: Clinical advancement requires immediate consensus on an optimal perinatal-sourced candidate, mandatory priming/EV depletion, validated quantitative potency assays, and Good Manufacturing Practice (GMP)-compliant manufacturing. With coordinated effort, first-in-human phase I trials could commence by 2028-2029, offering a novel, off-the-shelf paracrine therapy for solid tumors.